Percutaneous ethanol and lipiodol injection therapy for hepatocellular carcinoma

  • Authors:
    • Kazutaka Kurokohchi
    • Tsutomu Masaki
    • Yoshiaki Miyauchi
    • Toshiharu Funaki
    • Hirohito Yoneyama
    • Hisaaki Miyoshi
    • Shuhei Yoshida
    • Takashi Himoto
    • Asahiro Morishita
    • Naohito Uchida
    • Seishiro Watanabe
    • Shigeki Kuriyama
  • View Affiliations

  • Published online on: February 1, 2004     https://doi.org/10.3892/ijo.24.2.381
  • Pages: 381-387
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Radiofrequency ablation (RFA) therapy is of great significance in the treatment of hepatocellular carcinoma (HCC) or metastatic liver tumors. RFA is able to achieve widely coagulated necrosis in a few sessions without major complications. However, HCC cases exist that are resistant to RFA therapy for several reasons. In the present study, we performed injection of the mixture of ethanol and lipiodol (percutaneous ethanol-lipiodol injection therapy: PELIT) for HCCs that lacked clear visuality of the entire shape of the tumor by ultrasonography (US) or computed tomography (CT), or that were difficult to treat with RFA alone due to their locations in the liver or due to severe liver dysfunction of the patients. Local recurrence rates of HCC treated with PELIT were shown to be low in patients followed up for at least 4 months. In all patients treated with PELIT, lipiodol was accumulated in the entire region of the tumor after several trials of PELIT and the accumulation was kept for many months. The biopsy examination from the tumor treated with PELIT showed that HCC cells were totally destroyed by the PELIT. Although RFA therapy serves as a central role for the treatment of HCCs, PELIT, considered to be milder therapy, is likely to be important as a supportive treatment for HCCs and useful for the treatment of HCCs that are difficult to treat with RFA.

Related Articles

Journal Cover

February 2004
Volume 24 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kurokohchi K, Masaki T, Miyauchi Y, Funaki T, Yoneyama H, Miyoshi H, Yoshida S, Himoto T, Morishita A, Uchida N, Uchida N, et al: Percutaneous ethanol and lipiodol injection therapy for hepatocellular carcinoma. Int J Oncol 24: 381-387, 2004
APA
Kurokohchi, K., Masaki, T., Miyauchi, Y., Funaki, T., Yoneyama, H., Miyoshi, H. ... Kuriyama, S. (2004). Percutaneous ethanol and lipiodol injection therapy for hepatocellular carcinoma. International Journal of Oncology, 24, 381-387. https://doi.org/10.3892/ijo.24.2.381
MLA
Kurokohchi, K., Masaki, T., Miyauchi, Y., Funaki, T., Yoneyama, H., Miyoshi, H., Yoshida, S., Himoto, T., Morishita, A., Uchida, N., Watanabe, S., Kuriyama, S."Percutaneous ethanol and lipiodol injection therapy for hepatocellular carcinoma". International Journal of Oncology 24.2 (2004): 381-387.
Chicago
Kurokohchi, K., Masaki, T., Miyauchi, Y., Funaki, T., Yoneyama, H., Miyoshi, H., Yoshida, S., Himoto, T., Morishita, A., Uchida, N., Watanabe, S., Kuriyama, S."Percutaneous ethanol and lipiodol injection therapy for hepatocellular carcinoma". International Journal of Oncology 24, no. 2 (2004): 381-387. https://doi.org/10.3892/ijo.24.2.381